TrialHaematologica2018

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.

Farhad Ravandi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.